OneMedNet Corporation has finalized an agreement to integrate its real-world data platform with Palantir Foundry, accelerating AI-driven drug development workflows for life sciences firms.
The Minneapolis-based company, which operates under the NASDAQ ticker ONMD, provides de-identified clinical data from over 2,300 healthcare partner sites. Its network spans more than 90 million patient journeys and 270 million studies, covering multimodal diagnostic records such as radiology, cardiology, EEG, ECG, and electronic health records. The platform is designed to deliver regulatory-grade data for AI model training, validation, and drug discovery applications.
The collaboration leverages Palantir Foundry to streamline data processing, with contract execution completed within three weeks of initial contact. According to OneMedNet, cohort feasibility was achieved within minutes, while data validation was finalized within a week. The company positions its first-party data as critical for building AI models that perform in real-world clinical settings.
Aaron Green, President and CEO of OneMedNet, emphasized the demand for provider-sourced data among healthcare innovators. "Healthcare innovators are coming to OneMedNet because they see what it takes to build AI that performs in the real world: private clinical data sourced directly from healthcare providers," Green stated.
The agreement targets life sciences companies, medical device manufacturers, AI developers, and regulatory submissions requiring high-quality, de-identified clinical datasets for AI model development and validation.
